# Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects With Progressive Pulmonary Fibrosis (TETON-PPF)

> **NCT05943535** · PHASE3 · RECRUITING · sponsor: **United Therapeutics** · enrollment: 698 (estimated)

## Conditions studied

- Progressive Pulmonary Fibrosis
- Interstitial Lung Disease

## Interventions

- **DRUG:** Placebo
- **DRUG:** Inhaled Treprostinil
- **DEVICE:** Treprostinil Ultrasonic Nebulizer

## Key facts

- **NCT ID:** NCT05943535
- **Lead sponsor:** United Therapeutics
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2023-10-30
- **Primary completion:** 2027-11
- **Final completion:** 2027-11
- **Target enrollment:** 698 (ESTIMATED)
- **Last updated:** 2026-05-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05943535

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05943535, "Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects With Progressive Pulmonary Fibrosis (TETON-PPF)". Retrieved via AI Analytics 2026-06-04 from https://api.ai-analytics.org/clinical/NCT05943535. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*